Abstract
Six human β-galactoside α2,3-sialyltransferase genes, which are hST3Gal I-VI, have been cloned. Multiple genes encode enzymes with closely related catalytic specificities but different patterns of tissue expression. The multiple genes correspond to the control of various tissue specific regulators. Several studies have examined the transcriptional regulation of some human β-galactoside α2,3-sialyltransferases genes. Multiple mRNA forms differing only in the 5- untranslated regions have been identified in hST3Gal II, hST3Gal III, hST3Gal IV, hST3Gal V, and hST3Gal VI. These transcripts are produced by a combination of alternative splicing and promoter utilization, suggesting the transcriptional regulation of this gene depends on the use of alternative promoters, further suggesting that tissue-specific transcriptional regulation of these genes depends on the use of multiple genes and multiple promoters. The multiple regulatory pathways of these ubiquitous sialyltransferases may be differentially modulated in various cell types.
Keywords: Sialyltransferase, promoter, multiple gene, multiple promoter
Current Drug Targets
Title: Promoter Structure and Transcriptional Regulation of Human β-Galactoside α2, 3-Sialyltransferase Genes
Volume: 9 Issue: 4
Author(s): Akiyoshi Taniguchi
Affiliation:
Keywords: Sialyltransferase, promoter, multiple gene, multiple promoter
Abstract: Six human β-galactoside α2,3-sialyltransferase genes, which are hST3Gal I-VI, have been cloned. Multiple genes encode enzymes with closely related catalytic specificities but different patterns of tissue expression. The multiple genes correspond to the control of various tissue specific regulators. Several studies have examined the transcriptional regulation of some human β-galactoside α2,3-sialyltransferases genes. Multiple mRNA forms differing only in the 5- untranslated regions have been identified in hST3Gal II, hST3Gal III, hST3Gal IV, hST3Gal V, and hST3Gal VI. These transcripts are produced by a combination of alternative splicing and promoter utilization, suggesting the transcriptional regulation of this gene depends on the use of alternative promoters, further suggesting that tissue-specific transcriptional regulation of these genes depends on the use of multiple genes and multiple promoters. The multiple regulatory pathways of these ubiquitous sialyltransferases may be differentially modulated in various cell types.
Export Options
About this article
Cite this article as:
Taniguchi Akiyoshi, Promoter Structure and Transcriptional Regulation of Human β-Galactoside α2, 3-Sialyltransferase Genes, Current Drug Targets 2008; 9 (4) . https://dx.doi.org/10.2174/138945008783954998
DOI https://dx.doi.org/10.2174/138945008783954998 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry Contemporary Anticholinesterase Pharmaceuticals of Natural Origin and Their Synthetic Analogues for the Treatment of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Unraveling Potential Candidate Targets Associated with Expression of p16<sup>INK4a</sup> or p16 Truncated Fragment by Comparative Proteomics Analysis
Current Proteomics Wnt Signaling Pathway in Schizophrenia
CNS & Neurological Disorders - Drug Targets Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System
CNS & Neurological Disorders - Drug Targets The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
Current Medicinal Chemistry Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Iron Chelators as Potential Therapeutic Agents for Parkinsons Disease
Current Bioactive Compounds Mechanisms of Acupuncture Effect on Alzheimer’s Disease in Animal- Based Researches
Current Topics in Medicinal Chemistry Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Pyridinium Oxime Reactivators of Cholinesterase Inhibited by Diisopropyl- Fluorophosphate (DFP): Predictive Value of In-Vitro Testing for In-Vivo Efficacy
Mini-Reviews in Medicinal Chemistry Animal Models for Testing Anti-Prion Drugs
Current Topics in Medicinal Chemistry Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry FoxO Proteins: Regulation and Molecular Targets in Liver Cancer
Current Medicinal Chemistry Allosteric Modulation of Nicotinic Acetylcholine Receptors: The Concept and Therapeutic Trends
Current Pharmaceutical Design Natural Thiazoline-Based Cyclodepsipeptides from Marine Cyanobacteria: Chemistry, Bioefficiency and Clinical Aspects
Current Medicinal Chemistry Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design